Presented by Humacyte

Disclaimer: This webinar is the sole content of the Industry Sponsors and does NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies, or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.

Description
Join leading experts for an in-depth discussion on the science, clinical outcomes and real-world application of Symvess® Acellular Tissue Engineered Vessel (ATEV), a conduit innovation in vascular surgery in the last four decades specifically for the vascular trauma indication. 

Speakers

• Laura Niklason, MD, PhD, Founder, President, and CEO, Humacyte
  Dr. Niklason will provide an overview of Humacyte and a scientific analysis of the Symvess® Acellular Tissue Engineered Vessel (ATEV™) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.1 
• Todd Rasmussen, MD, Vascular Surgeon
  Dr. Rasmussen will review ATEV clinical evidence from completed studies and patient cases, and provide insights into intraoperative ATEV handling techniques. 

Interactive Discussion
The program will conclude with a live discussion session to address audience questions hosted by Dr. Niklason and Dr. Rasmussen, giving attendees the opportunity to engage directly with the faculty and explore this innovation in greater depth.

Target Audience
Vascular Surgeon
Vascular Trainee
Other types of Physicians
Vascular Nurses
Vascular Technologists
Physician Assistants
Nurse Practitioners
Hospital and Practice Administrators

This video is part of the Vascular Innovations Webinar Series